Cohort 1 | |||||||||
 | Age | Diagnosis at admission | Day of ICU | Secondary infection | microorganism | Antibiotic treatment | mHLA-DR (AB/C) | Injections of IFNγ | Day-15 outcome |
1 | 30 | Cardiac arrest | 10 | VAP | Pseudomonas aeruginosa | amikacin (4 days) + colimycin (2 days) + cefepim (2 days) | 2419 | 5 | alive |
2 | 83 | Postop cardiogenic shock | 29 | VAP | Pseudomonas aeruginosa, Stenotrophomonas maltophilia | ciprofloxacin (11 days) + ceftazidime (13 days) | 4092 | 6 | alive |
3 | 73 | Cardiogenic shock | 16 | VAP | Stenotrophomonas maltophilia, Pseudomonas aeruginosa | piperacillin + tazobactam (4 days) | 1492 | 4 | alive |
4 | 63 | Peritonitis | 16 | VAP | Pseudomonas aeruginosa | Imipenem (7 days) | 1427 | 3 | dead |
5 | 42 | Peritonitis | 10 | VAP, peritonitis | Pseudomonas aeruginosa, Aspergillus fumigatus | piperacillin+ tazobactam (10 days) | 1547 | 6 | alive |
6 | 64 | Peritonitis | 37 | Peritonitis VAP | Stenotrophomonas maltophilia + Enterobacter Cloacae + Enterococcus feacalis Enterobacter cloacae + Stenotrophomonas maltophilia | tigecycline + colimycin | 2666 | 3 | alive |
7 | 65 | Postoparative pneumonia | 134 | VAP | Streptococcus agalactiae | none | 3289 | 5 | alive |
8 | 56 | Pneumonia | 11 | VAP | Stenotrophomonas maltophilia EBV reactivation | piperacillin + tazobactam (10 days) | 4991 | 4 | alive |
9 | 34 | Pneumonia | 15 | VAP | Pseudomonas aeruginosa Aspergillus fumigatus | colimycine (15 days) amikacine (aerosolized) 15 days Voriconazole started | 5428 | 5 | alive |
10 | 56 | Cervical cellulitis septicemia | 13 | Perirenal abscess | Staphylococcus aureus | oxacilline + Pefloxacine (12 days) | 2056 | 7 | alive |
11 | 60 | Fasciitis | 38 | Fasciitis | Pseudomonas aeruginosa | Imipenem + amikacine (3 days) | 5132 | 5 | alive |
12 | 74 | Keto-acidosis | 40 | VAP, lung abcess, pleuresis | Pseudomonas aeruginosa, Citrobacter freundii | Imipenem (7 days) | 7073 | 4 | Alive |
13 | 82 | Rectal Fistulae & fasciitis | 9 | Tight muscle infection | Gram negative multiple bacteriaanaerobes | Piperacillin + tazobactam (4 days) Imipenem + amikacine (7 days) | 2168 | 3 | Alive |
Cohort 2 | |||||||||
Age | Diagnosis at admission | Infection focus | Delay between admission and IFNγ | Microorganism | Antibiotic treatment | SOFA-score at admission | mHLA-DR Expression (MFI) | Outcome | |
74 | Septic Shock | Abdominal | 4 | Unknown | Ceftriaxon | 12 | 16.0 | Death | |
73 | “ | Abdominal | 3 | Klebsiella pneumoniae | Ceftriaxon | 8 | 14.6 | Alive | |
74 | “ | Bilary | 1 | Multi-resistant E coli, Clostridium perfringens | Piperacillin / tazobactam, ceftriaxon erytromycin | 14 | 5.6 | Alive | |
80 | “ | Abdominal | 5 | Staphylococcus haemolyticus, Candida albicans | Vancomycin and Piperacillin / tazobactam, myfungin / fluconazole | 9 | 73.6 | Death |